Byetta sales take a hit as Amylin sets sights on Bydureon approval, pledges financial discipline
This article was originally published in Scrip
Executive Summary
As Amylin Pharmaceuticals works with the US FDA and the firm's partners Lilly and Alkermes to clear the final hurdles towards approval of their diabetes drug Bydureon, which was rejected for a second time this past October, the biotech intends to remain focused on managing its business and expenses "as carefully as we have over the past two years," said CEO Daniel Bradbury